arrow
G

Graeme R. Robb

AstraZeneca
H指数:25
被引数:2,055

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470; an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation

利用人体剂量预测指标推动AZD3470的发现;一种处于临床评价阶段的MTA协同PRMT5抑制剂

2026-05-220
PRE
Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug Design
2024-08-120
PRE
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity
2024-07-310
PRE
Development of a Series of Pyrrolopyridone MAT2A Inhibitors
2024-03-113
PRE
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390
2024-02-024
PRE
Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors
2024-01-163
PRE
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration

AZD4747的发现,这是一种有效且选择性的突变体GTPase KRASG12C抑制剂,具有明显的中枢神经系统穿透性

2023-07-0311
PRE
Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors

嘧啶并吡啶酮系列IRAK4抑制剂的鉴定和优化

2022-06-012
PRE
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the MutantGTPase KRASG12C

突变gtpase KRASG12C的共价变构抑制剂AZD4625的发现

2022-04-2637
PRE
Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft Model
2021-04-2628
OAAI
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors
2020-12-014
PREAI
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C
2020-02-0560
PREAI
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6
2018-10-17120
OAAI